Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Biochemistry

• Publication date

  2015-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.clinbiochem.2015.06.020PMID 26129879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.

  2015cited by this paper
• Maternal Serum Placental Growth Factor Isoforms 1 and 2 at 11-13, 20-24 and 30-34 Weeks' Gestation in Late-Onset Pre-Eclampsia and Small for Gestational Age Neonates

  2014cited by this paper
• Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies

  2014cited by this paper
• New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia

  2014cited by this paper
• Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

  2013cited by this paper
• Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease

  2011cited by this paper
• Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays.

  2011cited by this paper
• Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia.

  2010cited by this paper
• An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.

  2010cited by this paper
• Limit of blank, limit of detection and limit of quantitation.

  2008cited by this paper
• Latest Advances in Understanding Preeclampsia

  2005cited by this paper
• Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia.

  2005cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

  2004cited by this paper
• Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System

  2004cited by this paper
• Antibiotic use in relation to the risk of breast cancer

  2004cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• Pre-eclampsia

  2000cited by this paper
• Tris (2,2′-bipyridyl)ruthenium(II) electrogenerated chemiluminescence in analytical science

  1997cited by this paper
• Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

  1994cited by this paper
• Rare earth cryptates and homogeneous fluoroimmunoassays with human sera.

  1993cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I

  1983cited by this paper

• Prediction and Management of Preeclampsia: Literature Review

  2024cites this paper
• The Management of Preeclampsia: A Comprehensive Review of Current Practices and Future Directions

  2024cites this paper
• Advances in preeclampsia testing.

  2023cites this paper
• Analytical Performance and Quality Indicators of Fully Automated Immunoassays for sFlt-1 and PlGF.

  2022cites this paper
• Procalcitonin levels differences in preeclampsia and non preeclampsia

  2021cites this paper
• Applying the concept of uncertainty to the sFlt-1/PlGF cut-offs for diagnosis and prognosis of preeclampsia

  2021cites this paper
• Decision Threshold for Kryptor sFlt‐1/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting

  2021cites this paper
• Clinical Performance of The sFlt-1/PlGF Test For The Prediction of Preeclampsia Among Asymptomatic and Symptomatic Pregnant Women in Estonia: A Nested Case-Control Study

  2021cites this paper
• Decision-making based on sFlt-1/PlGF ratios: are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia?

  2020cites this paper
• Comparative study of sFlt-1/Plgf ratio with uterine artery doppler indices in prediction of preeclampsia at 22-24 weeks period of gestation

  2020cites this paper
• Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.

  2020cites this paper
• Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia.

  2020cites this paper
• Role of sFlt-1 and PlGF in the screening of small-for-gestational age neonates during pregnancy: A systematic review

  2019cites this paper
• [Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians].

  2019cites this paper
• Preeclampsia-Spectrum Hypertensive Disorders of Pregnancy: Gestational Hypertension, Preeclampsia, Eclampsia, Chronic Hypertension, and HELLP Syndrome

  2019cites this paper
• Intrauterine growth restriction, soluble fms-like tyrosine kinase-1 to placental growth factor ratio increase and preeclampsia.

  2019cites this paper
• Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?

  2019cites this paper
• Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.

  2018cites this paper
• Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at <32 weeks compared with ≥32 weeks.

  2018cites this paper
• Factores anti-angiogénicos y preeclampsia

  2018cites this paper
• Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®.

  2017cites this paper
• Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis

  2017influential citation
• Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.

  2016cites this paper
• Color Doppler ultrasound detection of uterine artery S / D , PI and RI in patients with preeclampsia and their correlation with disease severity

  2016cites this paper
• KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes

  2016cites this paper